Skip to search formSkip to main contentSkip to account menu

SN 38

Known as: SN-38, SN38 cpd 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

7-ethyl-10-hydroxycamptothecin
irinotecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
Targeting Colorectal Cancer Stem-Like Cells with Anti-CD133 Antibody-Conjugated SN-38 Nanoparticles.
Cancer stem-like cells play a key role in tumor development, and these cells are relevant to the failure of conventional… 
Highly Cited
2015
Highly Cited
2015
Enhanced Delivery of SN-38 to Human Tumor Xenografts with an Anti-Trop-2–SN-38 Antibody Conjugate (Sacituzumab Govitecan)
Purpose: This study examined the delivery of SN-38 to Trop-2–expressing tumors and assessed the constitutive products in the… 
Highly Cited
2009
Highly Cited
2009
Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
Highly Cited
2005
Highly Cited
2005
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics.
Highly Cited
2003
Highly Cited
2003
Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors.
Highly Cited
2001
Highly Cited
2001
Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
Breast cancer resistance protein (BCRP), an ABC half-transporter, is overexpressed in cancer cell lines selected with doxorubicin… 
Highly Cited
1998
Highly Cited
1998
UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
BACKGROUND Irinotecan (CPT-11) is metabolized by esterase to form a SN-38, which is further conjugated by UGT1A1. Genetic… 
Highly Cited
1996
Highly Cited
1996
Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells.
Topoisomerase I-targeting anticancer agents such as 7-ethyl-10-[4-(1-piperidyl)-1-piperidyl]carbonyloxy-camptothecin (CPT-11) and… 
Highly Cited
1996
Highly Cited
1996
Irinotecan is an active agent in untreated patients with metastatic colorectal cancer.
PURPOSE To determine the response rate, survival, and toxicity of the new anticancer agent, irinotecan (CPT-11), in the treatment… 
Highly Cited
1990
Highly Cited
1990
Establishment of a camptothecin analogue (CPT-11)-resistant cell line of human non-small cell lung cancer: characterization and mechanism of resistance.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)